New York Medical College

Research

Explore Research at NYMC

Heart attack. Angina. Stroke. Arrythmia. Heart failure. Coronary artery disease. Despite a 36 percent drop in mortality over the last 30 years, heart disease is still the number one killer in the nation.

 

There has never been a more pressing need for cardiovascular research.

At New York Medical College, waging and winning this battle is the underlying principle behind two research program project grants, significant NIH awards that support a broadly based, multifaceted research program with a specific objective. Translational studies pair collaborators from basic science and clinical departments to wage an attack from the flanks.

In Physiology: Vascular Endothelial Cells

In the Department of Physiology, Michael S. Wolin, Ph.D., professor, studies how reactive oxygen and nitric oxide control signaling systems that affect contractile function in coronary arteries. Thomas H. Hintze, Ph.D., professor and chairman of physiology, examines the pathophysiologic relevance of increasing and decreasing nitric acid production on the development of heart failure.

In Pharmacology: Blood Pressure Regulation

Hypertension sufferers are three times more likely to develop coronary artery disease and seven times more likely to suffer strokes; high blood pressure forces the heart to work harder than normal and speeds up the process of atherosclerosis in arteries.

Alberto Nasjletti, M.D., professor, is principal investigator of the program project grant in the Department of Pharmacology that explores “Hormonal Regulation of Blood Pressure.” The goal is to understand what regulates blood pressure using a genetic approach to identify the mechanisms of hypertension.

The four-part Program Project has been assembled to characterize the vascular and renal mechanisms of blood pressure regulation-under normal and hypertensive conditions. Michal L. Schwartzman, Ph.D., professor and chair of pharmacology, is focusing on the metabolism of arachidonic acid, a prostaglandin precursor from which 20-HETE (20-hydroxyeicosatetraenoic acid) is derived.

Dr. Nasjletti is involved with the carbon monoxide produced by arterial vessels to determine if it has any functional significance in blood pressure regulation, while Wenhui Wang, M.D, professor of pharmacology, is characterizing the interactions among nitric oxide, carbon monoxide and 20-HETE as they relate to renal function.

Individual Studies

Mairead A. Carroll, Ph.D., professor of pharmacology, examines the regulation of a recently discovered class of hormone-like factors, generated from arachidonic acid by cytochrome-P 450 enzymes, that affect blood vessel function and sodium transport in the kidney. Her team conducts experiments that probe the effects of cardiovascular hormones on levels of arachidonic acid and their derivatives in the kidneys. Their studies aim to clarify the role of arachidonic acid in the regulation of sodium excretion and the development of hypertension.

More research  in the Department of Pharmacology…

Epidemiological studies have shown that even in the absence of other risk factors, advanced age itself significantly increases of death from heart disease and cerebrovascular disease.

Akos Koller, M.D., Ph.D., professor, is studying the regulation of vasomotor tone of microvessels that are essential in the maintenance of tissue perfusion and blood pressure. He aims to reveal the early mechanisms responsible for the development of dysfunction of resistance vessels in order to find the optimal therapeutic strategies aiming to prevent and reduce microvascular complications in hypertension. The present focus of my investigation is the potential role of the altered the activity of the renin angiotensin system (RAS) in the microvascular wall.

More research  in the Department of Physiology…

Translational Research

Serving as the clinical link in cardiovascular research is William H. Frishman, M.D., professor and chairman of medicine, an internationally recognized clinical pharmacologist. He has completed more than 300 research protocols funded by the N.I.H. and private industry, and taken part in developing more than 100 cardiovascular drugs.

Michael S. Goligorsky, M.D., Ph.D., professor of medicine and of pharmacology and director of the Division of Nephrology, studies vascular complications in cardiovascular diseases such as diabetes and hypertension.

Thomas Hintze, Ph.D., professor and chairman of the Department of Physiology, examines the pathophysiologic relevance of increasing and decreasing nitric acid production on the development of heart failure. He also collaborates with Julian Stewart, M.D., Ph.D., professor of pediatrics, to study the effect of nitric oxide on the autonomic nervous system in orthostatic intolerance.

Anthony L. Pucillo, M.D., associate professor of medicine, is conducting a multi-center  trial to  contrast  the  relative  efficacy  of  carotid  artery  stenting  versus  carotid  endarterectomy  in  preventing  stroke, myocardial infarction and  death  in  a  30-day  peri-procedural  period,   and  stroke  ipsilateral  to  the  study  artery  over  the  follow-up  period.

Romeo  B. Mateo, M.D., assistant professor of surgery, is studying  whether  the  endovascular  repair  of  small  abdominal  aortic  aneurysms  (AAA)   using  the  AneuRx  AAA  Stent  Graft  is  superior  to  serial  imaging  surveillance  with  respect  to  the  frequent  AAA  rupture  or  AAA  related  death  over  a  three-year  follow-up  period.

Warren D. Rosenblum, M.D., associate professor of medicine, is conducting a multi-center  study  evaluating  the  efficacy  and  safety  of  Nesiritide  administered  in  addition  to  standard  care  vs.  placebo  administered  in  addition  to  standard  care  in  patients  with  acute  decompensated  heart  failure. Dr. Rosenblum is also conducting a randomized,  placebo-controlled study of oral  lixivaptan in  the  management  of  hyponatremia in  subjects  with  NYHA Class III/IV heart failure and  volume overload.

Page updated: March 31, 2014